Medicare AdvantagePrior AuthMedium impact
Quviviq (daridorexant) (Revised)
Humana·Sleep Medicine, Family Medicine, Internal Medicine +2 more·Medicare Advantage
Effective date
Jan 1, 2024
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated its step therapy policy for Quviviq (daridorexant), an insomnia medication. Members must now have previous treatment, contraindication, or intolerance to Belsomra (suvorexant) or trazodone before Quviviq will be covered.
Action Required
Immediately: Providers treating insomnia patients must document previous treatment, contraindication, or intolerance to Belsomra (suvorexant) or trazodone tablet before prescribing Quviviq (daridorexant) for Medicare Advantage members. Update EMR templates to include step therapy documentation requirements. Failure to meet criteria will result in coverage denials.